Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megha L Mehrotra

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|November 26, 2019
Understanding HIV Program Effects: A Structural Approach to Context Using the Transportability FrameworkMegha L Mehrotra, Maya L Petersen, Elvin H Geng
Journal of Acquired Immune Deficiency Syndromes (1999)|October 23, 2020
Brief Report: Seroadaptive Behaviors Varied Among Geographically Diverse iPrEx ParticipantsHong-Ha M Truong, Megha L Mehrotra, Robert M Grant, et al.
The Lancet. HIV|October 2, 2019
Mosaic effectiveness: measuring the impact of novel PrEP methodsDavid V Glidden, Megha L Mehrotra, David T Dunn, et al.
American Journal of Epidemiology|February 22, 2021
Transporting Subgroup Analyses of Randomized Controlled Trials for Planning Implementation of New InterventionsMegha L Mehrotra, Daniel Westreich, M Maria Glymour, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 4, 2021
Breaking Inertia: Movement Along the PrEP Cascade in a Longitudinal US National Cohort of Sexual Minority Individuals at Risk for HIVMegha L Mehrotra, Drew A Westmoreland, Viraj V Patel, et al.
Vaccine|September 18, 2024
Defining long COVID using a population-based SARS-CoV-2 survey in CaliforniaJake M Pry, Kalyani McCullough, Kristina Wen-Jeh Lai, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 14, 2019
Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx TrialMegha L Mehrotra, Daniel Westreich, Vanessa M McMahan, et al.
AIDS and Behavior|May 14, 2018
The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with MenMegha L Mehrotra, K Rivet Amico, Vanessa McMahan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 18, 2015
Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis TrialPeter J Kuebler, Brian I Shaw, Kaitlyn S Leadabrand, et al.
American Journal of Industrial Medicine|January 16, 2023
Evaluating the association between in-person work and the risk of SARS-CoV-2 infection through June 2021Erika Meza, Kristin J Cummings, Ximena P Vergara, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal of Acquired Immune Deficiency Syndromes (1999)|November 26, 2019
Understanding HIV Program Effects: A Structural Approach to Context Using the Transportability FrameworkMegha L Mehrotra, Maya L Petersen, Elvin H Geng
Journal of Acquired Immune Deficiency Syndromes (1999)|October 23, 2020
Brief Report: Seroadaptive Behaviors Varied Among Geographically Diverse iPrEx ParticipantsHong-Ha M Truong, Megha L Mehrotra, Robert M Grant, et al.
The Lancet. HIV|October 2, 2019
Mosaic effectiveness: measuring the impact of novel PrEP methodsDavid V Glidden, Megha L Mehrotra, David T Dunn, et al.
American Journal of Epidemiology|February 22, 2021
Transporting Subgroup Analyses of Randomized Controlled Trials for Planning Implementation of New InterventionsMegha L Mehrotra, Daniel Westreich, M Maria Glymour, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 4, 2021
Breaking Inertia: Movement Along the PrEP Cascade in a Longitudinal US National Cohort of Sexual Minority Individuals at Risk for HIVMegha L Mehrotra, Drew A Westmoreland, Viraj V Patel, et al.
Vaccine|September 18, 2024
Defining long COVID using a population-based SARS-CoV-2 survey in CaliforniaJake M Pry, Kalyani McCullough, Kristina Wen-Jeh Lai, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 14, 2019
Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx TrialMegha L Mehrotra, Daniel Westreich, Vanessa M McMahan, et al.
AIDS and Behavior|May 14, 2018
The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with MenMegha L Mehrotra, K Rivet Amico, Vanessa McMahan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 18, 2015
Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis TrialPeter J Kuebler, Brian I Shaw, Kaitlyn S Leadabrand, et al.
American Journal of Industrial Medicine|January 16, 2023
Evaluating the association between in-person work and the risk of SARS-CoV-2 infection through June 2021Erika Meza, Kristin J Cummings, Ximena P Vergara, et al.
Pageof 3